JP5346923B2 - 腫瘍増殖阻害化合物及びそれらの使用方法 - Google Patents

腫瘍増殖阻害化合物及びそれらの使用方法 Download PDF

Info

Publication number
JP5346923B2
JP5346923B2 JP2010506140A JP2010506140A JP5346923B2 JP 5346923 B2 JP5346923 B2 JP 5346923B2 JP 2010506140 A JP2010506140 A JP 2010506140A JP 2010506140 A JP2010506140 A JP 2010506140A JP 5346923 B2 JP5346923 B2 JP 5346923B2
Authority
JP
Japan
Prior art keywords
cells
treatment
cell
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010506140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525811A5 (enExample
JP2010525811A (ja
Inventor
オーサ・カルソン
ステイン オリヴァー・フォン
アレソウ・サールガリ
ニコライ・コウスネトソヴ
Original Assignee
インデックス・ファーマシューティカルズ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インデックス・ファーマシューティカルズ・アクチエボラーグ filed Critical インデックス・ファーマシューティカルズ・アクチエボラーグ
Publication of JP2010525811A publication Critical patent/JP2010525811A/ja
Publication of JP2010525811A5 publication Critical patent/JP2010525811A5/ja
Application granted granted Critical
Publication of JP5346923B2 publication Critical patent/JP5346923B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010506140A 2007-05-04 2008-04-30 腫瘍増殖阻害化合物及びそれらの使用方法 Expired - Fee Related JP5346923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92758407P 2007-05-04 2007-05-04
US60/927,584 2007-05-04
PCT/SE2008/050501 WO2008136748A1 (en) 2007-05-04 2008-04-30 Tumour growth inhibitory compounds and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013168777A Division JP5844779B2 (ja) 2007-05-04 2013-08-15 腫瘍増殖阻害化合物及びそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2010525811A JP2010525811A (ja) 2010-07-29
JP2010525811A5 JP2010525811A5 (enExample) 2011-06-16
JP5346923B2 true JP5346923B2 (ja) 2013-11-20

Family

ID=39943756

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010506140A Expired - Fee Related JP5346923B2 (ja) 2007-05-04 2008-04-30 腫瘍増殖阻害化合物及びそれらの使用方法
JP2013168777A Expired - Fee Related JP5844779B2 (ja) 2007-05-04 2013-08-15 腫瘍増殖阻害化合物及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013168777A Expired - Fee Related JP5844779B2 (ja) 2007-05-04 2013-08-15 腫瘍増殖阻害化合物及びそれらの使用方法

Country Status (6)

Country Link
US (1) US8309529B2 (enExample)
EP (2) EP2573176B1 (enExample)
JP (2) JP5346923B2 (enExample)
DK (1) DK2573176T3 (enExample)
ES (1) ES2581480T3 (enExample)
WO (1) WO2008136748A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507308A (ja) * 2008-11-04 2012-03-29 インデックス・ファーマシューティカルズ・アクチエボラーグ Ｃｎｓの炎症性疾患の治療のための化合物および方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2656850B1 (en) * 2007-10-05 2016-07-27 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
US20110182880A1 (en) * 2008-06-18 2011-07-28 Oliver Von Stein Combination Therapies Against Cancer
JP5749651B2 (ja) 2008-11-04 2015-07-15 インデックス・ファーマシューティカルズ・アクチエボラーグ 多形核細胞の動員および／または遊走を減少させる化合物および方法
US9157919B2 (en) * 2010-12-21 2015-10-13 Index Pharmaceuticals Ab Method for identifying biologically active oligonucleotides capable of modulating the immune system
WO2018174140A1 (ja) * 2017-03-23 2018-09-27 ナパジェン ファーマ，インコーポレテッド 癌細胞の接着活性阻害剤
EP3967307A1 (en) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
KR20240006547A (ko) * 2021-05-04 2024-01-15 주식회사 애스톤사이언스 Her2 백신 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498147B2 (en) 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
EP0772619B2 (en) * 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
WO2000061151A2 (en) * 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7534772B2 (en) * 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
BRPI0416079A (pt) * 2003-10-30 2007-01-02 Coley Pharm Gmbh análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
EP2656850B1 (en) * 2007-10-05 2016-07-27 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507308A (ja) * 2008-11-04 2012-03-29 インデックス・ファーマシューティカルズ・アクチエボラーグ Ｃｎｓの炎症性疾患の治療のための化合物および方法

Also Published As

Publication number Publication date
JP5844779B2 (ja) 2016-01-20
ES2581480T3 (es) 2016-09-06
EP2573176B1 (en) 2016-04-06
WO2008136748A1 (en) 2008-11-13
EP2160465A4 (en) 2011-04-13
EP2573176A1 (en) 2013-03-27
DK2573176T3 (en) 2016-08-01
US20100196356A1 (en) 2010-08-05
JP2013255508A (ja) 2013-12-26
EP2160465A1 (en) 2010-03-10
EP2160465B1 (en) 2013-01-02
US8309529B2 (en) 2012-11-13
WO2008136748A8 (en) 2009-07-23
JP2010525811A (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
JP5844779B2 (ja) 腫瘍増殖阻害化合物及びそれらの使用方法
JP6893608B2 (ja) がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用
Jego et al. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors
JP6885867B2 (ja) 組合せ腫瘍免疫療法
US20250255898A1 (en) Compositions and methods for tumor immunotherapy
JP6893594B2 (ja) 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
Wang et al. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics
WO2015148879A1 (en) Cancer immunotherapy compositions and methods
KR20210035805A (ko) 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
JP2018516252A (ja) がんの処置のための抗ＩＬ−１０抗体とＣｐＧ−Ｃ型オリゴヌクレオチドの併用
JP2023053338A (ja) Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
JP6952603B2 (ja) クラミジア活性化ｂ細胞プラットフォーム及びその方法
Leuchte et al. Innovative treatment concepts for cutaneous T-cell lymphoma based on microenvironment modulation
JP2011524899A (ja) がんの併用療法
WO2022265864A9 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
JP4837034B2 (ja) オリゴヌクレオチドまたはその機能的相同体、それらを含有する組成物およびｂ細胞腫瘍を治療するための方法
Batool et al. Toll-like receptors targeting technology for the treatment of lymphoma
CA3137136A1 (en) Aim2 inhibitors and uses thereof
US20230203504A1 (en) Immunomodulatory polynucleotides and uses thereof
JP7407452B2 (ja) がんの治療及び／又は予防のための医薬
Browning Combination Therapies with Interleukin-21 in Chronic Lymphocytic Leukemia
Cicchelero Mono-and combination immunotherapy in dogs with spontaneous tumors: stimulation of the adaptive and innate immune system against cancer and suppression of immunosuppressive immune cells
NZ750663A (en) Compositions and methods for cancer immunotherapy
WO2012099871A1 (en) Modulation of lrch4 activity and therapeutic application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130819

R150 Certificate of patent or registration of utility model

Ref document number: 5346923

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees